RecallDepth
Class II Ongoing

Carvedilol Tablets, USP, 12.5 mg, Rx only, a)500 Tablets, NDC 68462-164-05; b) 100 Tablets, NDC 68462-164-01, Manufactured for Glenmark Pharmaceuticals, NJ.

This recall is currently active, issued February 12, 2025. It was issued by Glenmark Pharmaceuticals Inc., Usa.

Company
Glenmark Pharmaceuticals Inc., Usa
Recall Initiated
January 22, 2025
Posted
February 12, 2025
Recall Number
D-0216-2025
Voluntary / Mandated
Voluntary: Firm initiated
Firm Location
Mahwah, NJ, United States
Official Source
View on FDA website ↗

Reason for Recall

CGMP Deviations:N-Nitroso Carvedilol I impurity (NNCI-I) were found to be failing per current FDA recommended limit.

Distribution

Nationwide in the U.S

Lot / Code Info

Lot numbers: a) 17230658, Exp.: 02/2025; 17230814,17230822, Exp.: 03/2025; 17231004,17231009,17231022, Exp.: 04/2025; 17231393,17231392, Exp.: 05/2025; 17231538, 17231541,17231542, Exp.: 06/2025; 17231710,17231718,17231721,17231722,17231730, Exp': 07/2025; 17232169, Exp.: 09/2025; 17232253, Exp.: 10/2025; 17240220,17240240, Exp.: 01/2026; 17240459, Exp.: 02/2026 b) 17230814, Exp.: 03/2025; 17231392, Exp.:05/2025; 17232260, Exp.: 10/2025.

More recalls by Glenmark Pharmaceuticals Inc., Usa

View all recalls by this company →

Other recent Class II Drug recalls